Skip to Content
Merck
All Photos(1)

Documents

SML3319

Sigma-Aldrich

WM-3835

≥98% (HPLC)

Synonym(s):

N′-(4-Fluoro-5-methylbiphenylcarbonyl)-3-hydroxybenzenesulfonohydrazide, WM 3835, WM3835, [1,1’-Biphenyl]-3-carboxylic acid, 4-fluoro-5-methyl-, 2-[(3-hydroxyphenyl)sulfonyl]hydrazide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H17FN2O4S
CAS Number:
Molecular Weight:
400.42
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

protect from light

color

white to beige

solubility

DMSO: soluble

storage temp.

−20°C

SMILES string

OC1=CC(S(NNC(C2=CC(C3=CC=CC=C3)=CC(C)=C2F)=O)(=O)=O)=CC=C1

Biochem/physiol Actions

WM-3835is a cell-permeable hydroxybenzenesulfonohydrazide compound that acts as a potent, selective, Ac-CoA competitive and reversible inhibitor of HBO1, KAT6A, and TIP60 acetyltransferases (IC50 = 0.030, 0.017 and 0.312 µM, respectively). WM-3835 is non-cytotoxic, dose-dependently, and rapidly decreases H3K14Ac levels (IC50 = 0.341 µM) and inhibits AML cells growth (IC50 = 0.297 µM in Molm13). Induces apoptosis, downregulates HOXA and IL-6 expression and up-regulates ALB secretion and delays hepatocyte and hMPC senescence. WM-1385 potently inhibits POS-1 xenograft growth in SCID mice (10 mg/kg, i.p.).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Laura MacPherson et al.
Nature, 577(7789), 266-270 (2019-12-13)
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulation that results in a block in differentiation and increased malignant self-renewal. Various epigenetic therapies aimed at reversing these hallmarks of AML have progressed into clinical trials, but most

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service